Sanofi shares an ambition to reach blockbuster status (sales over $1 billion) for its Beyfortus vaccine. Beyfortus sales reached 182 million euros, reflecting late deliveries in the US and the new ...
AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infants, opening up a major ...
The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centres for Disease Control and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback